[email protected] Raquest Quote

Arsenic Trioxide Cooperative

  1. Home
  2. Arsenic Trioxide Cooperative

Singleagent Arsenic Trioxide In The Treatment Of Newly

Jul 19, 2010 Purpose We previously reported our results with a single-agent arsenic trioxide (ATO) based regimen in newly diagnosed cases of acute promyelocytic leukemia (APL). The concern remained about the long-term outcome of this well-tolerated regimen. We report our long-term follow-up data on the same cohort. Patients and Methods From January 1998 to December 2004, 72 patients with PML/RAR APL ...

19101018 App B Substance Technical Guidelines

A. Fire Arsenic, arsenic Trioxide and Arsenic Trichloride are nonflammable. B. Reactivity 1. Conditions Contributing to instability Heat. 2. Incompatibility Hydrogen gas can react with inorganic arsenic to form the highly toxic gas arsine. III. Monitoring and Measurement Procedures.

Arsenic Compound Sensitizes Homologous Recombination

Sep 22, 2021 The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells. Int J Environ Res Public Health. 20107201832. CAS Article Google Scholar

Arsenic Trioxide Improves Eventfree And Overall Survival

Nov 11, 2010 Arsenic trioxide (As 2 O 3) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL) its role as consolidation treatment for patients in first remission has not been defined.We randomized 481 patients (age 15 years) with untreated APL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 courses of ...

Historic Arsenical Pesticide Research Final

sizes associated with arsenic in soils from residential properties were too large to have come from smelter stack emissions (Washington Group International, 2001). Drexler (2003) speciated arsenic from the residential soils and determined that the predominant form of arsenic

Retinoic Acid And Arsenic Trioxide For Acute Promyelocytic

Two-year event-free survival rates were 97% in the ATRAarsenic trioxide group and 86% in the ATRAchemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points P ...

Atra Arsenic Trioxide Ato And Gemtuzumab

Dec 02, 2016 Jeffrey E. Lancet, Anna Moseley, Rami S Komrokji, Steven E. Coutre, Daniel J. DeAngelo, Martin S. Tallman, Mark Litzow, Megan Othus, Frederick R Appelbaum ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL) Final Results of the SWOG/Alliance/ECOG S0535 Trial.

Use Of Arsenic Trioxide As2o3 In The Treatment Of

Apr 17, 2003 BACKGROUND. Approximately 2030% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) and an anthracycline develop recurrent disease.It has been reported that arsenic trioxide (As 2 O 3) is effective in this setting.The authors report the experience of The M. D. Anderson Cancer Center with As 2 O 3 in the treatment of patients with recurrent ...

Research Shows Survival Benefit For Leukemia Eurekalert

Jun 04, 2007 Arsenic trioxide was approved by the Food and Drug Administration nearly seven years ago for use in patients with APL who had not responded to, or had stopped responding to, standard first-line ...

Arsenic National Pesticide Information Center

Jun 29, 2021 Arsenic. Arsenic is a naturally occurring element that is widely distributed in soils and minerals. Humans are regularly exposed to small amounts of arsenic in the air we breathe, the water we drink and the plants we eat. Arsenic is used as a pesticide primarily to preserve wood from rot and decay. In the past, arsenic was also used in rat ...

Arsenic Trioxidebased Therapy Of Relapsed Acute

Jan 28, 2015 Arsenic trioxide (ATO) is presently regarded as the treatment of choice for relapsed APL after frontline therapy with ATRA and chemotherapy, yielding about 85% complete hematological remission (CR ...

Combination Treatment Of Arsenic Oxide And Antiandrogens

Jun 05, 2018 MURGO A J Clinical trials of arsenic trioxide in hematologic and solid tumors overview of the National Cancer Institute Cooperative Research and Development Studies, THE ONCOLOGIST, ALPHAMED PRESS, US, vol. 6, no. SUPPL 2, 1 January 2001 (2001-01-01), pages 22 - 28, XP002254637, ISSN 1083-7159, DOI 10.1634/THEONCOLOGIST.6-SUPPL_2-22 (A) (ISR)

Efficacy And Safety Of The Arsenic Trioxidelipiodol

Aug 20, 2021 Purpose . The goal of this study was to assess the clinical efficacy and safety of the arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib in the treatment of advanced hepatocellular carcinoma (HCC). Methods . From December 2015 to February 2017, a total of 87 patients were consecutively enrolled and underwent ATO-TACE (aTACE ...

Additive Antitumor Effect Of Arsenic Trioxide Combined

Background As an inorganic compound used to treat various cancers and other diseases, arsenic trioxide (As2O3) has been reported to induce cellular apoptosis in certain kinds of cancers including bladder cancer. The aim of the present study was to elucidate the crucial cooperative role of As2O3and intravesical bacillus Calmette-Guerin (BCG) immunotherapy and its ability to protect against bladder cancer by targeting the

Clinical Trials Of Arsenic Trioxide In Hematologic And

Arsenic trioxide inhibits growth and promotes apoptosis in many different cancer cell lines. The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkins lymphoma, Hodgkins disease, chronic

Clinical Trials Of Arsenic Trioxide In Hematologic And

Apr 01, 2001 In a study of arsenic trioxide for the treatment of AML, patients older than 65 years with refractory, relapsed, or newly diagnosed AML were eligible for this trial. The Eastern Cooperative Oncology Group recently activated a trial of the compound in patients with relapsed or refractory ALL.

Clinical Trials Of Arsenic Trioxide In Hematologic And

Arsenic trioxide National Cancer Institute Hematologic malignancy Solid tumor ABSTRACT Arsenic trioxide inhibits growth and promotes apopto-sis in many different cancer cell lines. The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hemato-

Arsenic Trioxide Accord European Medicines Agency

May 12, 2021 Arsenic trioxide Accord is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic translocation (when there is a swap of genes between two chromosomes). The translocation affects the way the white blood cells grow, and as a ...

Arsenic Trioxide Sensitizes Glioblastoma To A Myc Inhibitor

Jun 03, 2015 As a result, glucose carbon is completely away from mitochondria, and glutamine is essential to maintain TCA cycle activity, which made c-Myc-transformed cells susceptible to inhibition of mitochondrial electron transport chain36,39, which might explain cooperative effects of 10058F4 with arsenic trioxide, because arsenic trioxide is a ...

Arsenic Trioxide Uses Interactions Mechanism Of Action

Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.

Arsenic Trioxide Controls The Fate Of The Pmlrar

Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As 2 O 3 ) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RAR (a fusion protein containing sequences from ...

Arsenic Trioxide During Consolidation For Patients With

Feb 14, 2014 The outcome of treatment of acute promyelocytic leukaemia (APL) has significantly improved over the last two decades with the recognition of the importance of anthracyclines, the introduction of alltrans retinoic acid (ATRA) and arsenic trioxide (ATO), and improved supportive care measures.(Wang Chen, 2008 Sanz LoCoco, 2011) Following anthracyclinebased chemotherapy and ATRA ...

Oral Tetraarsenic Tetrasulfide Formula Versus

Oct 14, 2013 Purpose This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of an oral tetra-arsenic tetra-sulfide (As4S4) containing formula named the Realgar-Indigo naturalis formula (RIF) compared with intravenous arsenic trioxide (ATO) as both induction and maintenance therapies for newly diagnosed acute promyelocytic leukemia (APL). Patients and ...

Arsenic Inorganic Health Surveillance Guide For

Nov 27, 2020 Arsenic compounds such as arsenic trioxide are soluble in bodily fluids and cleared rapidly from the lungs. Less soluble arsenic compounds (calcium arsenate, lead arsenate, arsenic sulphide) are retained in the lungs and 80-90% of arsenic trioxide is absorbed by the gastrointestinal tract. Dermal absorption is likely to be low.

Apoptotic Efficacy Of Etomoxir In Human Acute Myeloid

Dec 15, 2014 Arsenic trioxide (ATO, Trisenox) is a clinically established drug for the treatment of acute promyelocytic leukemia (APL) . At low concentrations (0.251.0 M in plasma) the drug blocks cell growth and promotes terminal differentiation by disrupting the promyelocytic leukemia-retinoic acid receptor alpha (PML-RAR) oncogenic fusion protein ...

Arsenic Trioxide Replacing Or Reducing Chemotherapy In

Feb 09, 2021 , Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17) Results of a randomised, controlled, phase 3 trial. Lancet Oncol. 16, 1295 1305 (2015).

Arsenic Trioxide Side Effects Common Severe Long Term

Jan 24, 2021 Arsenic trioxide Side Effects. Medically reviewed by Drugs.com. Last updated on Jan 24, 2021. Consumer Professional In Summary. Commonly reported side effects of arsenic trioxide include pleural effusion, dyspnea, fever, leukocytosis, palpitations, prolonged qt interval on ecg, tachycardia, and weight gain.Other side effects include cardiac arrhythmia. See below for a comprehensive list of ...

Arsenic Trioxide Trisenox Ato Cancer Information

Arsenic trioxide (Trisenox, ATO) Arsenic trioxide is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocytic leukaemia (APL). How it works. Arsenic works by speeding up the death of leukaemic cells and encouraging normal blood cells to

Arsenic Early In Treatment Improves Survival For Leukemia

Nov 11, 2010 Arsenic trioxide is then used to get them back into remission, often followed by a bone marrow transplant to try to cure the patient. For this study, we used arsenic as an early consolidation therapy after the initial standard treatment to essentially, as one of our first patients described, seal the

Drinking Water Problems Arsenic How Can Arsenic Affect

Most agricultural uses of arsenic have been banned in the United States. The last agricultural use of inorganic arsenic, arsenic acid on cotton, was canceled voluntarily in 1993. Inorganic arsenic compounds (arsenic acid, arsenic trioxide and sodium arsenate) currently are used only in sealed ant baits and in wood preservatives.

Arsenic Toxicity Litfl Toxicology Library Toxicant

Nov 03, 2020 If there is a positive arsenic test from a heavy metal screen this need to distinguish between the organic (most likely cause) between inorganic exposure. Decontamination Whole bowel irrigation with polyethylene glycol if the patient is cooperative and presents with arsenic trioxide poisoning (radio-opaque).

Use Of Arsenic Trioxide In Remission Induction And

Sep 01, 2015 These data indicate that for high-risk patients, arsenic trioxide given as part of induction and in two cycles of consolidation can successfully substitute for intensification of chemotherapy, which typically involves the use of intermediate-dose or high-dose cytarabine, and

Table 1 Efficacy And Safety Of The Arsenic Trioxide

Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma Table 1

Oral Arsenic Trioxide Orh2014 Pharmacokinetic And

Daily intravenous arsenic trioxide administered with all-trans retinoid acid, the standard-of-care for acute promyelocytic leukemia, is costly and challenging to administer. ORH-2014 is a novel, oral arsenic trioxide formulation, consisting of micron-size drug particles with rapid dissolution and high bioavailability. We conducted a multicenter phase 1 dose-escalating study in patients with ...

Treatment Protocol For Relapsed Acute Promyelocytic

Sep 20, 2005 With arsenic trioxide (ATO) monotherapy remission rates over 80% were achieved and long-lasting molecular remissions are described. The drug was mostly well tolerated. ATO exerts a dose dependent dual effect on APL blasts, apoptosis in higher and partial differentiation in lower concentrations.